Computer modeling of bevacizumab drug distribution after intravitreal injection in rabbit and human eyes.

Macula clears our central vision and sharpens our visibility. The macula is positioned in the middle of the retinal tissue. Age-related macular degeneration (AMD) is a condition brought on by macular deterioration. In the United States, millions of elderly people suffer from AMD. There is no permanent cure if the disease is diagnosed at a later stage. AMD is an irreversible disease where the patient goes blind eternally. For retinal treatment, due to the material characteristics of the vitreous humor layer, it serves as the main barrier to drug transport to the retinal layer. Many treatments, including drug-based treatment, laser photocoagulation, and laser therapy, have been used for AMD disease. Anti-VEGF drugs have been proven most stable medication in AMD treatment that inhibits the action of vascular endothelial growth factor. One of the most suggested anti-VEGF drugs used in AMD treatment is bevacizumab using intravitreal injection. In our study, we have developed a spatially distributed pharmacokinetic model of the drug bevacizumab to measure time-drug concentration profiles throughout the vitreous and near the macula in rabbit and human eyes.